Published in Pathogens on October 09, 2015
Total Protein Profile and Drug Resistance in Candida albicans Isolated from Clinical Samples. Mol Biol Int (2016) 0.78
Candida albicans Pathogenesis: Fitting within the Host-Microbe Damage Response Framework. Infect Immun (2016) 0.76
Prevalence of Trichomonas vaginalis and Candida albicans among Brazilian Women of Reproductive Age. J Clin Diagn Res (2016) 0.75
Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev (2007) 15.66
Nonfilamentous C. albicans mutants are avirulent. Cell (1997) 13.83
Virulence factors of Candida albicans. Trends Microbiol (2001) 5.01
Engineered control of cell morphology in vivo reveals distinct roles for yeast and filamentous forms of Candida albicans during infection. Eukaryot Cell (2003) 4.71
Maintenance fluconazole therapy for recurrent vulvovaginal candidiasis. N Engl J Med (2004) 4.30
Candida albicans secreted aspartyl proteinases in virulence and pathogenesis. Microbiol Mol Biol Rev (2003) 4.07
The ALS gene family of Candida albicans. Trends Microbiol (2001) 3.93
The distinct morphogenic states of Candida albicans. Trends Microbiol (2004) 3.86
Growth of Candida albicans hyphae. Nat Rev Microbiol (2011) 3.02
Contributions of hyphae and hypha-co-regulated genes to Candida albicans virulence. Cell Microbiol (2005) 3.02
Candida albicans pathogenicity mechanisms. Virulence (2013) 2.60
Antifungal susceptibilities of Candida species causing vulvovaginitis and epidemiology of recurrent cases. J Clin Microbiol (2005) 2.26
Adhesion in Candida spp. Cell Microbiol (2002) 2.24
Emerging fungal diseases. Clin Infect Dis (2005) 2.03
Hydrolytic enzymes as virulence factors of Candida albicans. Mycoses (2005) 1.96
Candida albicans Hyr1p confers resistance to neutrophil killing and is a potential vaccine target. J Infect Dis (2010) 1.96
An insight into the antifungal pipeline: selected new molecules and beyond. Nat Rev Drug Discov (2010) 1.78
NDV-3, a recombinant alum-adjuvanted vaccine for Candida and Staphylococcus aureus, is safe and immunogenic in healthy adults. Vaccine (2012) 1.77
In vivo and ex vivo comparative transcriptional profiling of invasive and non-invasive Candida albicans isolates identifies genes associated with tissue invasion. Mol Microbiol (2007) 1.68
Protective role of antimannan and anti-aspartyl proteinase antibodies in an experimental model of Candida albicans vaginitis in rats. Infect Immun (1997) 1.68
Efficacy of the anti-Candida rAls3p-N or rAls1p-N vaccines against disseminated and mucosal candidiasis. J Infect Dis (2006) 1.64
Advances in combating fungal diseases: vaccines on the threshold. Nat Rev Microbiol (2006) 1.58
Evidence that members of the secretory aspartyl proteinase gene family, in particular SAP2, are virulence factors for Candida vaginitis. J Infect Dis (1999) 1.58
Rats clearing a vaginal infection by Candida albicans acquire specific, antibody-mediated resistance to vaginal reinfection. Infect Immun (1995) 1.50
From commensal to pathogen: stage- and tissue-specific gene expression of Candida albicans. Curr Opin Microbiol (2004) 1.44
Expression of Candida albicans SAP1 and SAP2 in experimental vaginitis. Infect Immun (1995) 1.39
Candida albicans dimorphism as a therapeutic target. Expert Rev Anti Infect Ther (2012) 1.34
Prevalence of recurrent vulvovaginal candidiasis in 5 European countries and the United States: results from an internet panel survey. J Low Genit Tract Dis (2013) 1.30
Synthetic glycopeptide vaccines combining beta-mannan and peptide epitopes induce protection against candidiasis. Proc Natl Acad Sci U S A (2008) 1.22
Local anticandidal immune responses in a rat model of vaginal infection by and protection against Candida albicans. Infect Immun (2000) 1.20
Fungal vaccines: real progress from real challenges. Lancet Infect Dis (2008) 1.16
Prevalence of vulvovaginal candidiasis and susceptibility to fluconazole in women. Am J Obstet Gynecol (2002) 1.16
Modulation of cell surface-associated mannoprotein antigen expression in experimental candidal vaginitis. Infect Immun (1994) 1.16
Candida albicans yeast and hyphae are discriminated by MAPK signaling in vaginal epithelial cells. PLoS One (2011) 1.15
Fungal morphogenetic pathways are required for the hallmark inflammatory response during Candida albicans vaginitis. Infect Immun (2013) 1.11
Human domain antibodies against virulence traits of Candida albicans inhibit fungus adherence to vaginal epithelium and protect against experimental vaginal candidiasis. J Infect Dis (2006) 1.11
Candida and candidiasis in HIV-infected patients: where commensalism, opportunistic behavior and frank pathogenicity lose their borders. AIDS (2012) 1.10
Beta-glucan-CRM197 conjugates as candidates antifungal vaccines. Vaccine (2010) 1.09
Fluconazole-resistant Candida albicans vulvovaginitis. Obstet Gynecol (2012) 1.04
Intravaginal and intranasal immunizations are equally effective in inducing vaginal antibodies and conferring protection against vaginal candidiasis. Infect Immun (2002) 1.03
Pathogenesis of Recurrent Vulvovaginal Candidiasis. Curr Infect Dis Rep (2002) 1.03
The 65 kDa mannoprotein gene of Candida albicans encodes a putative beta-glucanase adhesin required for hyphal morphogenesis and experimental pathogenicity. Cell Microbiol (2007) 1.02
The unique solution structure and immunochemistry of the Candida albicans beta -1,2-mannopyranan cell wall antigens. J Biol Chem (2001) 1.01
Recent progress in vaccines against fungal diseases. Curr Opin Microbiol (2012) 1.00
Recurrent vulvovaginal candidiasis. Mo Med (2006) 0.99
Development of vaccines for Candida albicans: fighting a skilled transformer. Nat Rev Microbiol (2013) 0.98
A virosomal vaccine against candidal vaginitis: immunogenicity, efficacy and safety profile in animal models. Vaccine (2012) 0.97
Resistance mechanisms in fluconazole-resistant Candida albicans isolates from vaginal candidiasis. Int J Antimicrob Agents (2006) 0.97
Candida vaginitis: when opportunism knocks, the host responds. PLoS Pathog (2014) 0.92
Vulvovaginal candidiasis from non-albicans species: retrospective study of recurrence rate after fluconazole therapy. J Reprod Med (2006) 0.92
A highly immunogenic recombinant and truncated protein of the secreted aspartic proteases family (rSap2t) of Candida albicans as a mucosal anticandidal vaccine. FEMS Immunol Med Microbiol (2011) 0.92
Vulvovaginal Candidiasis Caused by Non-albicans Candida Species: New Insights. Curr Infect Dis Rep (2010) 0.91
Aspartyl proteinases of Candida albicans and their role in pathogenicity. Med Mycol (2001) 0.91
Fungal cell wall vaccines: an update. J Med Microbiol (2012) 0.91
Phenotypic and functional characterization of vaginal dendritic cells in a rat model of Candida albicans vaginitis. Infect Immun (2006) 0.90
Efficacy of a genetically engineered Candida albicans tet-NRG1 strain as an experimental live attenuated vaccine against hematogenously disseminated candidiasis. Clin Vaccine Immunol (2009) 0.89
Vulvovaginal candidiasis. Obstet Gynecol Clin North Am (2003) 0.86
Active and passive immunization with rHyr1p-N protects mice against hematogenously disseminated candidiasis. PLoS One (2011) 0.85
Immune cell-mediated protection against vaginal candidiasis: evidence for a major role of vaginal CD4(+) T cells and possible participation of other local lymphocyte effectors. Infect Immun (2002) 0.84
New immunotherapeutic strategies to control vaginal candidiasis. Trends Mol Med (2002) 0.83
Human vaginal mucosal immune system: characterization and function. Gen Diagn Pathol (1998) 0.82
From memory to antifungal vaccine design. Trends Immunol (2012) 0.81
Management of recurrent vulvovaginal candidiasis: unresolved issues. Curr Infect Dis Rep (2006) 0.80
Protection against rat vaginal candidiasis by adoptive transfer of vaginal B lymphocytes. FEMS Yeast Res (2010) 0.80
The epidemiology of mycotic vulvovaginitis and the use of antifungal agents in suspected mycotic vulvovaginitis and its implications for clinical practice. West Indian Med J (2005) 0.79
Reduced fluconazole susceptibility of Candida albicans isolates in women with recurrent vulvovaginal candidiasis: effects of long-term fluconazole therapy. Diagn Microbiol Infect Dis (2009) 0.78
Candida antigens and immune responses: implications for a vaccine. Expert Rev Vaccines (2014) 0.76